Sign up
Pharma Capital

Summit Therapeutics boss to speak at DMD conference

CEO Glyn Edwards is to participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference
DMD
DMD is a wasting disease that primarily affects boys and young men

Glyn Edwards, chief executive officer of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT), is to speak at a New York life sciences conference this month.

The boss of the dual-listed drug discovery and development company, which is focused on advancing therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection, will participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference on 21 June 2017.

Edwards will also participate in one-to-one meetings at the conference. 

John-H.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.